The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Feasibility of outpatient CAR-T therapy for LBCL
Craig W. Freyer, PharmD, BCOP, Hospital of the University of Pennsylvania, Philadelphia, PA, discusses the considerations for moving CAR-T therapy to the outpatient setting, highlighting data from studies evaluating the safety of outpatient administration of axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel) in patients with large B-cell lymphoma (LBCL). In order to deliver outpatient CAR-T therapy safely, it is important to consider both patient and product characteristics, and ensure that patients can transition from inpatient to outpatient care and vice-versa seamlessly. Dr Freyer explains that while small study cohorts support the outpatient use of liso-cel and tisa-cel, the data for axi-cel is limited and indicates that more patients require hospital administration. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
